1. Home
  2. LIVN vs NNNN Comparison

LIVN vs NNNN Comparison

Compare LIVN & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIVN
  • NNNN
  • Stock Information
  • Founded
  • LIVN 1987
  • NNNN 2021
  • Country
  • LIVN United Kingdom
  • NNNN Germany
  • Employees
  • LIVN N/A
  • NNNN N/A
  • Industry
  • LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • LIVN Health Care
  • NNNN Health Care
  • Exchange
  • LIVN Nasdaq
  • NNNN Nasdaq
  • Market Cap
  • LIVN 2.1B
  • NNNN 2.2B
  • IPO Year
  • LIVN 1993
  • NNNN 2025
  • Fundamental
  • Price
  • LIVN $54.53
  • NNNN $43.04
  • Analyst Decision
  • LIVN Strong Buy
  • NNNN
  • Analyst Count
  • LIVN 7
  • NNNN 0
  • Target Price
  • LIVN $59.71
  • NNNN N/A
  • AVG Volume (30 Days)
  • LIVN 583.7K
  • NNNN 49.3K
  • Earning Date
  • LIVN 10-29-2025
  • NNNN 01-01-0001
  • Dividend Yield
  • LIVN N/A
  • NNNN N/A
  • EPS Growth
  • LIVN N/A
  • NNNN N/A
  • EPS
  • LIVN N/A
  • NNNN 0.06
  • Revenue
  • LIVN $1,309,329,000.00
  • NNNN $8,185,146.00
  • Revenue This Year
  • LIVN $11.29
  • NNNN N/A
  • Revenue Next Year
  • LIVN $6.59
  • NNNN N/A
  • P/E Ratio
  • LIVN N/A
  • NNNN $802.78
  • Revenue Growth
  • LIVN 8.23
  • NNNN 21.95
  • 52 Week Low
  • LIVN $32.48
  • NNNN $5.18
  • 52 Week High
  • LIVN $58.91
  • NNNN $55.65
  • Technical
  • Relative Strength Index (RSI)
  • LIVN 50.60
  • NNNN N/A
  • Support Level
  • LIVN $56.42
  • NNNN N/A
  • Resistance Level
  • LIVN $57.53
  • NNNN N/A
  • Average True Range (ATR)
  • LIVN 1.35
  • NNNN 0.00
  • MACD
  • LIVN -0.70
  • NNNN 0.00
  • Stochastic Oscillator
  • LIVN 10.25
  • NNNN 0.00

About LIVN LivaNova PLC

UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

Share on Social Networks: